Lin L et al. reported that YAP1 enhances resistance to RAF and MEK-targeted cancer therapies resistance, revealing that YAP1 and RAF or MEK combined inhibition of synthetic lethality is a promising strategy to enhance treatment response and patient survival [47]; while Lee JE et al. found that YAP1 inhibition restores the sensitivity of EGFR-TKI in lung adenocarcinoma having primary or acquired EGFR-TKI resistance [54]. Here, YAP1 is linked to lung adenocarcinoma.